EQRX ($NASDAQ:EQRX): Analysts have expressed a positive outlook on EQRx Inc., with the average rating being “Hold”. EQRx Inc. is an innovative biopharmaceutical company specializing in researching and developing novel treatments for patients with unmet medical needs. Since its inception, the company has focused on bringing more affordable and accessible treatments to markets around the world. The “Hold” rating is based on a number of factors, such as the potential of the company’s treatments, the financial performance of the company, and the overall market sentiment. Analysts believe that EQRx Inc. has the potential to become a major player in the industry, and they are optimistic about its future prospects. The current target price for EQRx Inc. suggests that investors should maintain a neutral stance towards the stock.
However, there is still considerable upside potential when considering the company’s long-term growth prospects. As such, investors should continue to monitor EQRx Inc.’s progress in order to make an informed investment decision.
Analysts on Wall Street are giving a positive outlook for EQRx Inc. On Friday, the company’s stock opened at $2.2 and closed at the same price, up by 0.9% from last closing price of $2.2. Overall, the analysts are positive on the company’s future prospects and believe that they can maintain their current price level. This has led to a steady increase in investor confidence regarding the company’s stock performance. It appears that EQRx Inc may have some positive momentum going forward. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Eqrx. EQRx_Inc_Target_Price_Set_at_Hold_Rating”>More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Eqrx. EQRx_Inc_Target_Price_Set_at_Hold_Rating”>More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Eqrx. EQRx_Inc_Target_Price_Set_at_Hold_Rating”>More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Eqrx are shown below. EQRx_Inc_Target_Price_Set_at_Hold_Rating”>More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we recently conducted an analysis of EQRX’s fundamentals. Our Risk Rating has found that EQRX is a high risk investment in terms of financial and business aspects. We have detected two risk warnings in the company’s cashflow statement and financial journal. If you would like to know more, please become a registered user and take a look. We are sure that our analysis will help you make an educated decision about your investment. EQRx_Inc_Target_Price_Set_at_Hold_Rating”>More…
Risk Rating Analysis
Star Chart Analysis
The competition between EQRx Inc and its competitors is fierce. Each company is vying for a share of the market and each has its own unique strengths and weaknesses.
CureVac NV is a Dutch biopharmaceutical company that focuses on the development of cancer treatments and vaccines. The company has a market cap of 1.59B as of 2022 and a Return on Equity of -20.8%. The company’s focus on cancer treatments and vaccines makes it a unique player in the biopharmaceutical industry.
Lantern Pharma Inc is a clinical stage biopharmaceutical company focused on developing targeted cancer therapies. The company’s lead product is LP-100, a first-in-class small molecule inhibitor of the androgen receptor (AR) that is in clinical development for the treatment of castration-resistant prostate cancer. Lantern Pharma Inc has a market cap of 60.8M as of 2022, a Return on Equity of 16.74%. The company’s focus on developing targeted cancer therapies makes it an appealing investment for those looking to tap into the growing biopharmaceutical sector.
– BioXcel Therapeutics Inc ($NASDAQ:BTAI)
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company, which focuses on improving patient outcomes by identifying and investigating potential therapeutic applications of existing drugs. The company’s lead product candidate, BXCL501, is a sublingual thin film formulation of diazepam for the treatment of acute repetitive seizures and status epilepticus. The company was founded by Vimal Mehta in September 2013 and is headquartered in Branford, CT.
Wall Street analysts have given EQRx Inc a “Hold” rating on average, indicating that the stock is not expected to perform significantly in the near future. Analysts agree that the current target price for the stock is unlikely to change significantly. Investing in EQRx is therefore best suited for investors looking for a stable return over the long-term, rather than looking for short-term gains. The lack of upside potential should be weighed against the consistency of returns for investors considering investing in EQRx.